about
Alterations of the mitochondrial proteome caused by the absence of mitochondrial DNA: A proteomic viewProteomic analysis of podocyte exosome-enriched fraction from normal human urineHuman Proteinpedia enables sharing of human protein dataThe proteomic to biology inference, a frequently overlooked concern in the interpretation of proteomic data: a plea for functional validation.A novel strategy using MASCOT Distiller for analysis of cleavable isotope-coded affinity tag data to quantify protein changes in plasma.Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease.ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke.Detection of biomarkers of stroke using SELDI-TOF.Imaging mass spectrometry using peptide isoelectric focusing.Proteomic profiling in an animal model of acute pancreatitis.Identification of post-mortem cerebrospinal fluid proteins as potential biomarkers of ischemia and neurodegeneration.Applications of mass spectrometry for quantitative protein analysis in formalin-fixed paraffin-embedded tissues.Meta-analysis of genome-wide association studies identifies six new Loci for serum calcium concentrationsComprehensive proteome analysis by chromatographic protein prefractionation.Comparison of Cardiac and Non-Cardiac Biomarkers for Risk Stratification in Elderly Patients with Non-Massive Pulmonary Embolism.Quantification of HER2 by Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded (FFPE) Breast Cancer Tissues.Heart-fatty acid-binding protein as a marker for early detection of acute myocardial infarction and stroke.Proteomic analysis of human bile and potential applications for cancer diagnosis.Using bioinformatic resources in the proteomic analysis of biological fluids.Renal fibrosis and proteomics: current knowledge and still key open questions for proteomic investigation.Bile proteome in health and disease.Proteomics in mechanistic toxicology: history, concepts, achievements, caveats, and potential.Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold?Metabolomic analysis of urine samples by UHPLC-QTOF-MS: Impact of normalization strategies.Proteomic analysis of heat shock-induced protection in acute pancreatitis.Identification of hemoglobin variants by top-down mass spectrometry using selected diagnostic product ions.Assessment of the influence of the patient's inflammatory state on the accuracy of a haptoglobin selected reaction monitoring assay.Role of proteomics to differentiate between benign and potentially malignant pancreatic cysts.A versatile electrophoresis system for the analysis of high- and low-molecular-weight proteins.Delayed production of IL-18 in lungs and pancreas of rats with acute pancreatitis.Analysis of the pancreatic low molecular weight proteome in an animal model of acute pancreatitis.A Population-Based Model to Consider the Effect of Seasonal Variation on Serum 25(OH)D and Vitamin D Status.Accelerated digestion for high-throughput proteomics analysis of whole bacterial proteomes.Quantitative mass spectrometry analysis of intact hemoglobin A2 by precursor ion isolation and detection.PICarver: a software tool and strategy for peptides isoelectric focusing.Time-course proteomic analysis of taurocholate-induced necrotizing acute pancreatitis.An integrated approach for comparative proteomic analysis of human bile reveals overexpressed cancer-associated proteins in malignant biliary stenosis.Identification of brain cell death associated proteins in human post-mortem cerebrospinal fluid.Cardiac biomarkers and clinical scores for risk stratification in elderly patients with non-high-risk pulmonary embolism.Bile carcinoembryonic cell adhesion molecule 6 (CEAM6) as a biomarker of malignant biliary stenoses.
P50
Q24309072-981FE13B-F618-4FC0-B594-BBD558B96999Q24313258-A9094E85-4A0B-4027-9E80-3F02961FD57AQ28267923-81C7287F-AD1D-43EB-BC79-CD06F92B41D1Q30700824-24BB1DCF-7DC9-4CD4-B0C8-E5926B871B60Q30996137-A4C3B39D-B0C4-4015-AB02-7DF036728662Q31099384-5C3E888F-B80C-4FB7-9F44-E08F38D514E4Q31099397-0753BAD2-8C5A-43E7-B196-F59F8F3AE643Q33266742-004C6454-5DED-4523-B0E6-4F3A34153B2EQ33357404-23CFCA4E-591D-4BEA-8D43-731DB6FD2D17Q33358442-7B8EFEDE-44B8-4C93-AEB0-2E015ED1879FQ34335853-6924B1B2-05E0-4C82-9928-498EC90D1D66Q34693949-94A92071-869E-4834-BBA1-5875D1F9D5C8Q34998326-D66D204B-17CE-4AB5-A02C-CAAF4195CB3DQ35750478-872F6FFF-A34A-4D0B-B4DC-1312B8D1FB3AQ36028048-3B170991-FBF1-4D00-B380-96AF44E18B6CQ36134039-D3E81C0E-7E05-43D8-A760-FAA91C586002Q36202893-2648EF56-CDAA-4088-9C3C-3E1FE953E079Q37505061-2E5BFACA-3BA4-4A65-8205-D5CD1583EA14Q37817126-1D3283D1-BD2C-4257-A61D-BA2E0843B66FQ37885033-411F698A-2BF1-4A6F-9E04-29C3B39FA35BQ38201380-D10D9CCE-62D4-46E6-A19A-C41671B2679AQ38244067-6C46B071-C5CF-49D4-97B4-8BE4AAD60CEAQ38857856-407F7924-69C1-4025-ADDD-E02059D00C12Q39020567-B0EFABCD-8A26-4D97-80AC-12814A28D839Q40349436-FEF2C6E8-E963-45DA-9472-97D87906DE79Q41264294-073A5832-24E3-4B0F-ADCD-1962254A52B0Q42085201-4958A3BB-6646-4CED-9EFA-629CD4BC0B47Q42594706-5B185F8E-5609-4329-AD56-5A1615FD1F15Q42648212-E229538E-547E-47D8-AEA3-B847617C4B4FQ42754304-52D6FB3A-B74D-4E9E-BC2F-559A9920BBBFQ42983839-DA062C42-2E4F-4995-997C-BE3EC3DB1899Q43241661-3D75B908-3A91-4E8F-A3A6-FD8E558FF4BDQ43601192-20F725F6-8A12-4B67-BECB-14F9D67AB7BEQ43705624-053E49BB-82D8-4758-BC0F-338611ED99CDQ44844454-62BAA448-613F-4772-8005-DCA03D291790Q45613413-F1D9E651-5EAA-4DA4-A397-8E8D46A2712EQ47969491-72F061C2-07CA-499A-B7AC-F4A6FD541084Q48477695-ACC41DAB-E17E-4D2D-88B5-A2CED72B4963Q48495725-D602F137-E1AA-4937-A455-9A44CE292318Q50873207-7397D921-9E16-43EA-A8EB-DAB4B2F2D230
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Pierre Lescuyer
@ast
Pierre Lescuyer
@en
Pierre Lescuyer
@es
Pierre Lescuyer
@nl
Pierre Lescuyer
@sl
type
label
Pierre Lescuyer
@ast
Pierre Lescuyer
@en
Pierre Lescuyer
@es
Pierre Lescuyer
@nl
Pierre Lescuyer
@sl
prefLabel
Pierre Lescuyer
@ast
Pierre Lescuyer
@en
Pierre Lescuyer
@es
Pierre Lescuyer
@nl
Pierre Lescuyer
@sl
P106
P21
P31
P496
0000-0001-6986-8738